PREDICTING HUMAN TUMOR RESPONSE BY 31P MRS

描述：此应用程序来自DU。此应用程序的总体目标是 建议是评估从31-P导出的参数的能力 磁共振波谱（MRS）和1H磁共振成像 (MRI)评估预后和监测治疗效果， 肿瘤性疾病患者。申请人将在当地学习 接受术前化疗的晚期乳腺癌， 放疗+热疗。为了实现这一目标，申请人 建议在研究设计中研究1H MR 1图像引导的31-P MRS 它结合了系列研究和强大的三维光谱 与MR图像空间相关的定位。本研究将 作为前瞻性、合作临床研究试验进行 结合明确定义的临床终点和技术质量 控制使用31-P MRS，申请人将测量肿瘤 磷代谢水平，pH值和获得适当的代谢 指标使用1H MR 1，申请人将测量肿瘤T@， 将初始肿瘤坏死估计为体积百分比， 用顺磁性造影剂增强，例如Magnevist或Prohance。 将在启动前进行系列MR 1和MRS 化疗，首次放疗前0-48小时，0-48 第一次热疗后24-96小时，以及 去做手术MRAS和MR 1数据将与临床和 对治疗的组织学反应。工作假设是， 治疗前和治疗后近端31-P MRS代谢物水平、pH值，以及 T2值将是治疗结果的预后。

DESCRIPTION: This application is from DU. The overall goal of this proposal is to evaluate the ability of parameters derived from 31-P magnetic resonance spectroscopy (MRS) and 1H magnetic resonance imaging (MRI) to assess prognosis and monitor therapeutic effectiveness in patients with neoplastic disease. The applicants will study locally advanced breast cancer treated with preoperative chemotherapy and radiation + hyperthermia. To accomplish this goal, the applicants propose to investigate 1H MR1 image guided 31-P MRS in a study design which incorporates serial studies with robust three dimensional spectral localization with spatial correlation to MR images. This study will be undertaken as a prospective, cooperative clinical research trial incorporating well defined clinical endpoints and technical quality control. With 31-P MRS, the applicants will measure tumor phosphometabolite levels, pH and derive appropriate metabolic indicators. With 1H MR1, the applicants will measure tumor T@ and estimate initial tumor necrosis as the volume percent which does not enhance with a paramagnetic contrast agent, e.g. Magnevist or Prohance. Serial MR1 and MRS will be performed prior to initiation of chemotherapy, 0-48 hours prior to the first radiation treatment, 0-48 hours following the first hyperthermia treatment, and 24-96 hours prior to surgery. The MRAS and MR1 data will be correlated with clinical and histologic response to therapy. The working hypotheses are that pretherapy and proximal posththerapy 31-P MRS metabolite levels, pH, and t2 values will be prognostic of treatment outcome.